Dataset Information

Binational cohort study comparing the management and outcomes of pregnant women with a BMI >50-59.9 kg/m² and those with a BMI ?60 kg/m².

ABSTRACT:

Objectives

To compare the management, maternal and perinatal outcomes of women with a body mass index (BMI) ?60?kg/m² with women with a BMI >50-59.9?kg/m².

Design

International collaborative cohort study.

Setting

Binational study in the UK and Australia.

Participants

UK: all pregnant women, and Australia: women who gave birth (birth weight ?400?g or gestation ?20 weeks) METHODS: Data from the Australasian Maternity Outcomes Surveillance System and UK Obstetric Surveillance System. Management, maternal and infant outcomes were compared between women with a BMI ?60?kg/m² and women with a BMI >50-59.9?kg/m², using unconditional logistic regression.

Results

The sociodemographic characteristics and previous medical histories were similar between the 111 women with a BMI ?60?kg/m² and the 821 women with a BMI >50-59.9?kg/m². Women with a BMI ?60?kg/m² had higher odds of thromboprophylaxis usage in both the antenatal (24% vs. 12%; OR 2.25, 95%?CI 1.39 to 3.64) and postpartum periods (78% vs. 66%; OR 1.68, 95%?CI 1.04 to 2.70). Women with BMI ?60?kg/m² had nearly double the odds of pre-eclampsia/eclampsia (adjusted OR 1.83 (95% CI 1.01 to 3.30)). No other maternal or perinatal outcomes were statistically significantly different. Severe adverse outcomes such as perinatal death were uncommon in both groups thus limiting the power of these comparisons. The rate of perinatal deaths was 18 per 1000 births for those with BMI ?60?kg/m²; 12 per 1000 births for those with BMI >50-59.9?kg/m²; those with BMI ?60?kg/m² had a non-significant increased odds of perinatal death (unadjusted OR 1.46, 95%?CI 0.31 to 6.74).

Conclusions

Women are managed differently on the basis of BMI even at this extreme as shown by thromboprophylaxis. The pre-eclampsia result suggests that future research should examine whether weight reduction of any amount prior to pregnancy could reduce poor outcomes even if women remain extremely obese.

SUBMITTER: McCall SJ

PROVIDER: S-EPMC6089316 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Binational cohort study comparing the management and outcomes of pregnant women with a BMI >50-59.9 kg/m<sup>2</sup> and those with a BMI ≥60 kg/m<sup>2</sup>.

McCall Stephen J SJ Li Zhuoyang Z Kurinczuk Jennifer J JJ Sullivan Elizabeth E Knight Marian M

BMJ open 20180810 8

<h4>Objectives</h4>To compare the management, maternal and perinatal outcomes of women with a body mass index (BMI) ≥60 kg/m<sup>2</sup> with women with a BMI >50-59.9 kg/m<sup>2</sup>.<h4>Design</h4>International collaborative cohort study.<h4>Setting</h4>Binational study in the UK and Australia.<h4>Participants</h4>UK: all pregnant women, and Australia: women who gave birth (birth weight ≥400 g or gestation ≥20 weeks) METHODS: Data from the Australasian Maternity Outcomes Surveillance System a ...[more]

PMID: 30099391

Similar Datasets

Project description:IntroductionLeft gastric artery embolisation (LGAE) is a well-established treatment for major upper gastrointestinal (GI) bleeding when control is not established via upper GI endoscopy and recently has shown promising results for weight loss in small single arm studies. LGAE could be a treatment option in between our current tier-3 and tier-4 services for obesity. EMBIO is a National Institute for Health Research funded trial, a multicentre double-blinded randomised controlled trial between Imperial College National Health Service Trust and University College London Hospital, comparing LGAE versus Placebo procedure. The key aims of the trial is to evaluate LGAE efficacy on weight loss, its mechanism of action, safety profile and obesity-related comorbidities.Methods and analysis76 participants will be recruited from the existing tier-3 database after providing informed consent. Key inclusion criteria include adults aged 18-70 with a body mass index 35-50 kg/m2 and appropriate anatomy of the left gastric artery and coeliac plexus on CT Angiogram. Key exclusion criteria included previous major abdominal and bariatric surgery, weight >150 kg, type 2 diabetes on any medications other than metformin and the use of weight modifying medications. Participants will undergo mechanistic visits 1 week prior to the intervention and 3, 6 and 12 months postintervention. Informed consent will be received from each participant and they will be randomised in a 1:1 ratio to left gastric artery embolisation and placebo treatment. Blinding strategies include the use of moderate doses of sedation, visual and auditory isolation. All participants will enter a tier-3 weight management programme postintervention. The primary analysis will estimate the difference between the groups in the mean per cent weight loss at 12 months.Ethics and disseminationThis trial shall be conducted in full conformity with the 1964 Declaration of Helsinki and all subsequent revisions. Local research ethics approval was granted by London-Central Research Ethics Committee, (Reference 19/LO/0509) on 11 October 2019. The Medicines and Healthcare products Regulatory Agency (MHRA) issued the Letter of No Objection on 8 April 2022 (Reference CI/2022/0008/GB). The trial's development and progress are monitored by an independent trial steering committee and data monitoring and ethics committee. The researchers plan to disseminate results at conferences, in peer- reviewed journals as well as lay media and to patient organisations.Trial registration numberISRCTN16158402.

Project description:Although obesity with its comorbidities is linked with higher cancer risk, the data on genome stability in the obese/severely obese are scarce. This is the first study with three DNA damage assessment assays (Fpg-modified and alkaline comet assays and micronucleus cytome assay) performed on a severely obese population (n = 53) where the results were compared with daily intake of food groups, nutrient intake, dietary inflammatory index (DII), and anthropometric and biochemical parameters usually measured in obese individuals. Results demonstrated the association between DNA damage levels and a decrease in cell proliferation with anthropometric measurements and the severity of obese status, together with elevated levels of urates, inorganic phosphates, chlorides, and hs troponin I levels. DII was connected with oxidative DNA damage, while BMI and basal metabolic rate (BMR) were associated with a decrease in cell proliferation and DNA damage creation. Measured daily BMR and calculated daily energy intake from the food frequency questionnaire (FFQ) demonstrated no significant difference (1792.80 vs. 1869.86 kcal day-1 mean values). Groups with higher DNA damage than expected (tail intensity in comet assay >9% and >12.4%, micronucleus frequency >13), consumed daily, weekly, and monthly more often some type of food groups, but differences did not show a clear influence on the elevated DNA damage levels. Combination of all three DNA damage assays demonstrated that some type of damage can start earlier in the obese individual lifespan, such as nuclear buds and nucleoplasmic bridges, then comes decrease in cell proliferation and then elevated micronucleus frequencies, and that primary DNA damage is not maybe crucial in the overweight, but in severely obese. Biochemically changed parameters pointed out that obesity can have an impact on changes in blood cell counts and division and also on genomic instability. Assays were able to demonstrate groups of sensitive individuals that should be further monitored for genomic instability and cancer prevention, especially when obesity is already connected with comorbidities, 13 different cancers, and a higher mortality risk with 7-10 disease-free years loss. In the future, both DNA damage and biochemical parameters should be combined with anthropometric ones for further obese monitoring, better insight into biological changes in the severely obese, and a more individual approach in therapy and treatment. Patients should also get a proper education about the foodstuff with pro- and anti-inflammatory effect.

Dataset Information

Binational cohort study comparing the management and outcomes of pregnant women with a BMI >50-59.9 kg/m² and those with a BMI ?60 kg/m².

Objectives

Design

Setting

Participants

Results

Conclusions

Publications

Binational cohort study comparing the management and outcomes of pregnant women with a BMI >50-59.9 kg/m<sup>2</sup> and those with a BMI ≥60 kg/m<sup>2</sup>.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Binational cohort study comparing the management and outcomes of pregnant women with a BMI >50-59.9 kg/m2 and those with a BMI ?60 kg/m2.

Objectives

Design

Setting

Participants

Results

Conclusions

Publications

Binational cohort study comparing the management and outcomes of pregnant women with a BMI >50-59.9 kg/m<sup>2</sup> and those with a BMI ≥60 kg/m<sup>2</sup>.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Binational cohort study comparing the management and outcomes of pregnant women with a BMI >50-59.9 kg/m² and those with a BMI ?60 kg/m².